screen_shot_2014-05-22_at_09

PM Society announces new co-chairs

pharmafile | May 22, 2014 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing PRIME, farrow, jones, o'brien, pm society 

The PM Society is set to expand its reach across pharma and service firms through the new appointments of co-chairs Rachel Farrow (pictured) and Carwyn Jones.

Under their leadership 20 to 30 new committee recruits will be identified to support the executive team according to their expertise in key areas – the Digital interest group, Advertising Awards, Digital Media Awards, Training and education, Patient engagement, NHS partnerships and Market Access.

At the same time, Eamon O’Brien has been confirmed as the lead for the PM Society’s PriMe flexible modular training programme.

Advertisement

Farrow has been on the PM Society Committee for eight years, is a former vice-chair and also chairs the PM Society Digital Media Awards. She has worked in the healthcare comms industry for 22 years, managing several agencies, and is currently an independent consultant.

Jones is managing director at the Earthworks, a healthcare comms agency which is part of the OPEN Health group. He has been on the PM Society Committee for four years, and is the digital lead for the Society.

O’Brien is managing director of CR&C Organisation and an experienced coach and facilitator. He has been in the pharma industry for nearly 30 years.

Jones says: “We are at a transition period in pharmaceutical and healthcare marketing where we must embrace a move to incorporate digital, but traditional marketing channels, techniques and values continue to have an important role.”

Related Content

The Pharma Files: With Colin Williams from Astellas Pharma

Pharmafile chats with Colin Williams, Head of Marketing Excellence, Global Capabilities, Learning & Development at …

Winners announced for 2025 PM Society Awards

The pharma marketing and healthcare communications industry gathered for the 39th PM Society Awards on …

biogen_austria_238

Biogen Alzheimer’s treatment accepted into EMA’s PRIME scheme

Biogen (NASDAQ: BIIB) has announced that the European Medicines Agency (EMA) has accepted its investigational …

The Gateway to Local Adoption Series

Latest content